Genomictree Inc.
228760
Helyezés a részvények között
#18734
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Részvényárfolyam
$7.00
Piaci kapitalizáció
$171.81M
Változás (1 nap)
6.44%
Változás (1 év)
-47.27%
Ország
KR
Kereskedés Genomictree Inc. (228760)
Kategória
Healthcare
Genomictree Inc. (228760) részvényárfolyamának története
Legmagasabb napi záróár: $7.30 ekkor: 2026-10-01
Legalacsonyabb napi záróár: $3.98 ekkor: 2017-04-01
Legalacsonyabb napi záróár: $3.98 ekkor: 2017-04-01
Genomictree Inc. részvényárfolyamának története 2017 és 2026 között
Éves részvényárfolyam teljesítmény
| Év | Teljesítmény |
|---|---|
| 2026 (TTM) | -34.69% |
| 2025 | 31.68% |
| 2024 | 6.73% |
| 2023 | 91.06% |
| 2022 | -34.74% |
| 2021 | -21.56% |
| 2020 | -30.26% |
| 2019 | -19.05% |
| 2018 | 267.23% |
| 2017 | 0.00% |
Hasonló cégek vagy versenytársak részvényárai
| Vállalat | Részvényár | Változás 1év% | Ország |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
